Management of osteosarcoma

Current Treatment Options in Oncology

Volumn 7, Issue 6, 2006, Pages 444-455

  Whelan, Jeremy ^a   Seddon, Beatrice ^a   Perisoglu, Martha ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOXYPEPTIDASE G2; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDIOTYPIC ANTIBODY; IFOSFAMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 105AD7; MONOCLONAL ANTIBODY CD55; MURAMYL TRIPEPTIDE; NEW DRUG; OXALIPLATIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHOSPHATIDYLETHANOLAMINE; RADIOISOTOPE; RAZOXANE; TAXANE DERIVATIVE; TRABECTIDIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE METASTASIS; BRAIN DISEASE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DERMATITIS; DISABILITY; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENTIATION; DRUG RESPONSE; EUROPE; GASTROINTESTINAL SYMPTOM; HAIR FOLLICLE; HEARING LOSS; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; INTERNATIONAL COOPERATION; LIVER TOXICITY; MEDICAL SPECIALIST; MUCOSA INFLAMMATION; NEPHROTOXICITY; NONHUMAN; OSTEOSARCOMA; OUTCOMES RESEARCH; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROGNOSIS; REVIEW; RISK REDUCTION; SOLID TUMOR; TEAMWORK; TREATMENT PLANNING; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; OSTEOSARCOMA; RANDOMIZED CONTROLLED TRIALS;

EID: 33750708230     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0020-y     Document Type: Review

References (62)

1. Virtanen A, Pukkala E, Auvinen A: Incidence of bone and soft tissue sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients. Int J Cancer 2006, 118:1017-1021.
2. Merletti F, Richiardi L, Bertoni F et al.: Occupational factors and risk of adult bone sarcomas: a multicentric case-control study in Europe. Int J Cancer 2006, 118:721-727.
3. Friedman MA, Carter SK: The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 1972, 4:482-510.
4. Cortes EP, Holland JF, Wang JJ, et al.: Amputation and adriamycin in primary osteosarcoma. N Engl J Med 1974, 291:998-1000.
5. Jaffe N, Frei EI, Traggis D: Adjuvant methotrexate citrovorum factor treatment of osteogenic sarcoma. N Engl J Med 1974, 291:996-997.
6. Rosen G, Tan C, Sanmaneechai A, et al.: The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer 1975, 35:936-945.
7. Rosen G, Murphy ML, Huvos AG, et al.: Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 1976, 37:1-11.
8. Rosen G, Marcove RC, Caparros B, et al.: Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979, 43:2163-2177.
9. Rosen G, Caparros B, Huvos AG, et al.: Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982, 49:1221-1230.
10. Meyers PA, Heller G, Healey J, et al.: Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992, 10:5-15.
11. Saeter G, Alvegard TA, Elomaa I, et al.: Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 1991, 9:1766-1775.
12. Provisor AJ, Ettinger LJ, Nachman JB, et al.: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997, 15:76-84.
13. Winkler K, Beron G, Delling G, et al.: Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988, 6:329-337.
14. Fuchs N, Bielack SS, Epler D, et al.: Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998, 9:893-899.
15. Bacci G, Picci P, Ruggieri P, et al.: Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 1990, 65:2539-2553.
16. Bacci G, Picci P, Ferrari S, et al.: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993, 72:3227-3238.
17. Bramwell VH, Burgers M, Sneath R, et al.: A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992, 10:1579-1591.
18. Souhami RL, Craft AW, Van der Eijken JW, et al.: Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997, 350:911-917.
19. Lewis IJ, Nooij M: Chemotherapy at standard or increased dose intensity in patients with operable osteosarcoma of the extremity; a randomised controlled trial conducted by the European Osteosarcoma Intergroup (ISRCTN 86294690). Abstract presented at the Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 31-June 3, 2003.
20. Meyers PA, Schwartz CL, Krailo M, et al.: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005, 23:2004-2011.
21. Fidler IJ, Sone S, Fogler WE, Barnes ZL: Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci U S A 1981, 78:1680-1684.
22. MacEwen EG, Kurzman ID, Rosenthal RC, et al.: Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 1989, 81:935-938.
23. Kleinerman ES, Jia SF, Griffin J, et al.: Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol 1992, 10:1310-1316.
24. Kleinerman ES, Meyers PA, Raymond AK, et al.: Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol 1995, 17:181-193.
25. Kleinerman ES: Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Clin N Amer 1995, 9:927-938.
26. Romet-Lemonne JL, Mills B, Fridman WH, Munsell M: Prospectively planned analysis of data from a phase III study of liposomal muramyltripeptide phosphatidylethanolamine in the treatment of osteosarcoma. J Clin Oncol 2005, 23:6437-6438.
27. Huvos AG, Rosen G, Marcove RC: Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977, 101:14-18.
28. Goorin AM, Schwartzentruber DJ, Devidas M, et al.: Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003, 21:1574-1580.
29. Bacci G, Ferrari S, Longhi A, et al.: Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma. J Clin Oncol 2003, 21:4662-4663.
30. Bacci G, Picci P, Ferrari S, et al.: Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities: the recent experience at the Rizzoli Institute. Cancer Reat Res 1993, 62:299-308.
31. Bacci G, Ferrari S, Bertoni F, et al.: Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/ Osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000, 18:4016-4027.
32. Meyers PA, Gorlick R, Heller G, et al.: Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998, 16:2452-2458.
33. Ferrari S, Smeland S, Mercuri M, et al.: Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005, 23:8845-8852.
34. The European and American Osteosarcoma Study Group: The EURAMOS I trial. Available at: http://www.euramos.org. Accessed August 9, 2006.
35. Einhorn S, Strander H: Is interferon tissue specific? Effect of human leukocyte and fibroblast interferons on the growth of lymphoblastoid and osteosarcoma cell lines. J Gen Virol 1977, 35:573-577.
36. Hofmann V, Groscurth P, Morant R, et al.: Effects of leukocyte interferon (E. coli) on human bone sarcoma growth in vitro and in the nude mouse. Eur J Cancer Clin Oncol 1985, 21:859-863.
37. Brosjo O: Osteosarcoma and interferon. Studies of human xenografts in the nude mouse. Acta Orthop Scand Suppl 1989, 229:1-36.
38. Adamson A, Aparisi T, Brostrom LA: Interferon treatment of osteosarcoma. Pontificiae Acad Scient Scripta Varia 1979, 43:383-406.
39. Strander H, Bauer HC, Brosjo O, et al.: Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol 1995, 34:877-880.
40. Muller CR, Smeland S, Bauer HC, et al.: Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol 2005, 44:475-480.
41. Manara MC, Serra M, Benini S, et al.: Effectiveness of type I interferons in the treatment of multidrug resistant osteosarcoma cells. Int J Oncol 2004, 24:365-372.
42. Takaoka A, Hayakawa S, Yanai H, et al.: Integration of interferon-alpha/ beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003, 424:516-523.
43. Stein U, Walther W, Shoemaker RH: Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br J Cancer 1996, 74:1384-1391.
44. Pritchard-Jones K, Spendlove I, Wilton C, et al.: Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br J Cancer 2005, 92:1358-1365.
45. Anderson PM, Wiseman GA, Dispenzieri A, et al.: High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002, 20:189-196.
46. Franzius C, Schuck A, Bielack SS: High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002, 20:1953-1954.
47. Bielack SS, Kempf-Bielack B, Delling G, et al.: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20:776-790.
48. Jaffe N, Carrasco H, Raymond K, et al.: Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer 2002, 95:2202-2210.
49. Machak GN, Tkachev SI, Solovyev YN, et al.: Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc 2003, 78:147-155.
50. DeLaney TF, Park L, Goldberg SI, et al.: Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 2005, 61:492-498.
51. Wu F, Wang ZB, Chen WZ, et al.: Extracorporeal high intensity focused ultrasound ablation in the treatment of 1038 patients with solid carcinomas in China: an overview. Ultrason Sonochem 2004, 11:149-154.
52. Smith RB, Apostolakis LW, Karnell LH, et al.: National Cancer Data Base report on osteosarcoma of the head and neck. Cancer 2003, 98:1670-1680.
53. Strauss SJ, McTiernan A, Whelan JS: Late relapse of osteosarcoma: implications for follow-up and screening. Pediatr Blood Cancer 2004, 43:692-697.
54. Chou AJ, Merola PR, Wexler LH, et al.: Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2005, 104:2214-2221.
55. Bacci G, Briccoli A, Longhi A, et al.: Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 2005, 44:748-755.
56. Kempf-Bielack B, Bielack SS, Jurgens H, et al.: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005, 23:559-568.
57. Hauben EI, Bielack S, Grimer R, et al.: Clinico-histologic parameters of osteosarcoma patients with late relapse. Eur J Cancer 2006, 42:460-466.
58. Widemann BC, Balis FM, Kempf-Bielack B, et al.: High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004, 100:2222-2232.
59. Patel SR, Papadopoulos NE, Plager C, et al.: Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Cancer 1996, 78:741-744.
60. McTiernan A, Whelan J: A phase II study of docetaxel for the treatment of recurrent osteosarcoma. Sarcoma 2004, 8:71-76.
61. Laverdiere C, Kolb EA, Supko JG, et al.: Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003, 98:832-840.
62. Winkler K, Baron G, Kotz R, et al.: Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 1984, 2:617-624.